Regeneron gets US, EU review for myasthenia gravis drug (REGN)
· seekingalpha.com
Regeneron (REGN) and Alnylam Pharmaceuticals (ALNY) stock are in focus as myasthenia gravis therapy cemdisiran undergoes U.S. and EU reviews. Read more here.
The U.S. and European regulators have accepted Regeneron’s (REGN) marketing applications for cemdisiran, an experimental therapy developed with Alnylam Pharma...